{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:50:03Z","timestamp":1791575403633,"version":"4.3.4"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"41","license":[{"start":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:00:00Z","timestamp":1791504000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,9]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>While immune checkpoint inhibitors (ICIs) have reshaped cancer care, population-level patterns of infection-related involvement at death among cancer decedents remain incompletely characterized. We analyzed &gt;25 million US cancer deaths recorded in Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER; 1999\u20132023), excluding deaths with COVID-19 as the underlying cause. Infection-related involvement was defined using infection-related multiple-cause-of-death codes among decedents with cancer as the underlying cause. To approximate treatment context at the population level, malignancies were grouped by tumor-site\u2013based likelihood of ICI exposure (a proxy rather than observed receipt), and temporal changes were evaluated using Joinpoint regression and interrupted time-series (ITS) models anchored to 2015, corresponding to the period of broad clinical adoption of ICIs. The proportion of cancer-underlying-cause deaths with infection-related multiple causes increased from 7.98% in 2009\u20132013 to 8.65% in 2017\u20132019 (+0.67 percentage points) in the prespecified period comparison. Joinpoint analysis identified a 2015 inflection, shifting from a pre-2015 decline to a sustained post-2015 increase (APC, +1.42% through 2023). Post-2015, cancers in the high\u2013ICI-likelihood group (including melanoma, kidney, lung, and stomach cancers) showed a larger relative increase in infection-related multiple causes than low\u2013ICI-likelihood cancers (+16.2% vs +6.7%), and ITS models supported a steeper post-2015 slope after accounting for the pandemic period. These findings indicate that infection-related conditions listed on death certificates among US cancer decedents have increased since 2015, with larger rises observed in tumor sites more likely to be treated with ICIs. Further work using patient-level treatment data is needed to determine whether these temporal patterns reflect immunotherapy exposure, shifts in case mix, or changes in certification and coding practices.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000051069","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:01:28Z","timestamp":1791572488000},"page":"e51069","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["National trends in infection-related mortality among US cancer decedents in the immunotherapy era (1999\u20132023)"],"prefix":"10.1097","volume":"105","author":[{"given":"Lu","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jundan","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefei","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heran","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Oncology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20261009","first-page":"12","article-title":"Cancer statistics, 2024.","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"R2-20261009","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.idc.2020.02.004","article-title":"Infectious complications of immune checkpoint inhibitors.","volume":"34","author":"Abers","year":"2020","journal-title":"Infect Dis Clin North Am"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1093\/cid\/ciw539","article-title":"The Spectrum of serious infections among patients receiving immune checkpoint blockade for the treatment of melanoma.","volume":"63","author":"Del Castillo","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R5-20261009","first-page":"1","article-title":"Deaths: final data for 2021.","volume":"73","author":"Murphy","year":"2024","journal-title":"Natl Vital Stat Rep"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events.","volume":"9","author":"Brahmer","year":"2021","journal-title":"J ImmunoTher Cancer"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41571-020-0352-8","article-title":"Moving towards personalized treatments of immune-related adverse events.","volume":"17","author":"Esfahani","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.10.017","article-title":"Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.","volume":"107","author":"Kanjanapan","year":"2019","journal-title":"Eur J Cancer"},{"key":"R9-20261009","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1001\/jamaoncol.2023.6025","article-title":"Immunotherapy initiation at the end of life in patients with metastatic cancer in the US.","volume":"10","author":"Kerekes","year":"2024","journal-title":"JAMA Oncol"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/(SICI)1097-0258(20000215)19:3<335::AID-SIM336>3.0.CO;2-Z","article-title":"Permutation tests for joinpoint regression with applications to cancer rates.","volume":"19","author":"Kim","year":"2000","journal-title":"Stat Med"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-147-8-200710160-00010","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"147","author":"von Elm","year":"2007","journal-title":"Ann Intern Med"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1208\/s12248-021-00574-0","article-title":"Cancer immunotherapy update: FDA-approved checkpoint inhibitors and companion diagnostics.","volume":"23","author":"Twomey","year":"2021","journal-title":"AAPS J"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3390\/cancers12030738","article-title":"Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence.","volume":"12","author":"Vaddepally","year":"2020","journal-title":"Cancers (Basel)"},{"key":"R15-20261009","first-page":"348","article-title":"Interrupted time series regression for the evaluation of public health interventions: a tutorial.","volume":"46","author":"Bernal","year":"2017","journal-title":"Int J Epidemiol"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1365-2710.2002.00430.x","article-title":"Segmented regression analysis of interrupted time series studies in medication use research.","volume":"27","author":"Wagner","year":"2002","journal-title":"J Clin Pharm Ther"},{"key":"R17-20261009","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s11523-021-00824-3","article-title":"Risk of infection with immune checkpoint inhibitors: a systematic review and meta-analysis.","volume":"16","author":"Petrelli","year":"2021","journal-title":"Target Oncol"},{"key":"R18-20261009","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/imr.13388","article-title":"Immune checkpoint inhibitors in infectious disease.","volume":"328","author":"King","year":"2024","journal-title":"Immunol Rev"},{"key":"R19-20261009","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update.","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"R20-20261009","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1001\/jamaoncol.2022.4666","article-title":"Systemic anticancer therapy at the end of life-changes in usage pattern in the immunotherapy era.","volume":"8","author":"Canavan","year":"2022","journal-title":"JAMA Oncol"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1001\/jamaoncol.2023.1891","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer.","volume":"9","author":"Sun","year":"2023","journal-title":"JAMA Oncol"},{"key":"R22-20261009","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3390\/cancers15010081","article-title":"Impact of infections in patients receiving pembrolizumab-based therapies for non-small cell lung cancer.","volume":"15","author":"Burns","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R23-20261009","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.3390\/ph16081119","article-title":"Opportunistic infections and immune-related adverse events associated with administering immune checkpoint inhibitors: a narrative review.","volume":"16","author":"Oca\u00f1a-Guzm\u00e1n","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"R24-20261009","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/EDE.0000000000001597","article-title":"Analysis of multiple causes of death: a review of methods and practices.","volume":"34","author":"Bishop","year":"2023","journal-title":"Epidemiology"},{"key":"R25-20261009","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ije\/dyt221","article-title":"Fixed effects analysis of repeated measures data.","volume":"43","author":"Gunasekara","year":"2014","journal-title":"Int J Epidemiol"},{"key":"R26-20261009","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.2014.16153","article-title":"Methods for evaluating changes in health care policy: the difference-in-differences approach.","volume":"312","author":"Dimick","year":"2014","journal-title":"JAMA"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000051069","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T19:01:31Z","timestamp":1791572491000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000051069"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,9]]},"references-count":25,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000051069","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,9]]},"assertion":[{"value":"2026-03-10","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}